Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma

Clinical Cancer Research

Volumn 7, Issue 8, 2001, Pages 2563-2572

  Solorzano, Carmen C ^a   Baker, Cheryl H ^a   Tsan, Rachel ^a   Traxler, Peter ^b   Cohen, Pamela ^b   Buchdunger, Elisabeth ^b   Killion, Jerry J ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENETHYLAMINO 6 (HYDROXYL)PHENYL 7H PYRROLO[2,3 D]PYRIMIDINE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEMCITABINE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; CELL DIVISION; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; LYMPHOKINES; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PYRIMIDINES; PYRROLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBONUCLEOTIDE REDUCTASES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034881294     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Angiogenesis in cancer, vascular, rheumatoid and other diseases
2. Angiogenic factors
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
4. Pancreatic carcinoma
5. Cancer of the pancreas
6. Pancreatic carcinoma in perspective: A continuing challenge
7. Cancer statistics, 1999
8. Trends in pancreatic cancer mortality in Europe, 1955-1989
9. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
10. Production of transforming growth factor α in human pancreatic cancer cells: Evidence for a superagonist autocrine cycle
11. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α
12. Induction and expression of amphiregulin in human pancreatic cancer
13. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer
14. Overexpression of HER2/neu oncogene in human pancreatic carcinoma
15. Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles
16. Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo
17. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
18. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum
19. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice
20. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma
21. The role of vascular endothelial growth factor in pathological angiogenesis
22. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
23. Transforming growth factor-α: A more potent angiogenic mediator than epidermal growth factor
24. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
25. Reciprocal paracrine interactions between tumour cells and endothelial cells: The "angiogenesis progression" hypothesis
26. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
27. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
28. Preclinical profile of PKI 166, a novel and potent EFF-R tyrosine kinase inhibitor for clinical development
29. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
30. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma
31. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice
32. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells
33. Triggering signaling cascades by receptor tyrosine kinases
34. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells
35. In vivo toxicity, pharmacokinetics, and anticancer activity of genistein linked to recombinant human epidermal growth factor
36. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
37. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
38. Conditioned switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
39. Regulation of distinct steps of angiogenesis by different angiogenic molecules
40. Expression of interleukin-8 correlates with vascularity in human gastric carcinomas
41. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells
42. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-α: Balance between growth and death signals
43. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
44. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression
45. Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation